
Annual report 2025
added 02-12-2026
AVITA Medical Revenue 2011-2026 | RCEL
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue AVITA Medical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 71.6 M | 64.3 M | 50.1 M | 34.4 M | 14 M | 14.3 M | 5.4 M | 881 K | 907 K | 748 K | 2.11 M | 2.53 M | 2.57 M | 3.43 M | 3.34 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 71.6 M | 748 K | 18 M |
Quarterly Revenue AVITA Medical
| 2025-Q3 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 17.1 M | 18.5 M | - | 19.5 M | 15.2 M | 11.1 M | - | 13.6 M | 11.8 M | 10.6 M | - | 9.09 M | 8.34 M | 7.54 M | - | 7.02 M | 10.3 M | 8.76 M | 5.1 M | 5.06 M | 5.1 M | 5.06 M | 3.26 M | 3.25 M | 2.46 M | 1.71 M | 1.04 M | 269 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 19.5 M | 269 K | 8.36 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Medtronic PLC
MDT
|
33.5 B | $ 86.75 | 0.2 % | $ 112 B | ||
|
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | ||
|
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
12.3 M | - | 1.37 % | $ 20.5 M | ||
|
Acutus Medical
AFIB
|
7.16 M | - | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | ||
|
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | ||
|
InspireMD
NSPR
|
8.98 M | $ 1.75 | -2.23 % | $ 113 M | ||
|
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | ||
|
Orthofix Medical
OFIX
|
822 M | $ 11.8 | 0.68 % | $ 467 M | ||
|
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | ||
|
Inogen
INGN
|
349 M | $ 6.39 | 1.11 % | $ 170 M | ||
|
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | ||
|
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | ||
|
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | ||
|
Insulet Corporation
PODD
|
2.71 B | $ 221.66 | -1.71 % | $ 15.6 B | ||
|
AxoGen
AXGN
|
225 M | $ 33.48 | 2.67 % | $ 1.54 B | ||
|
Profound Medical Corp.
PROF
|
7.2 M | $ 5.36 | 4.08 % | $ 180 M | ||
|
CONMED Corporation
CNMD
|
1.37 B | $ 36.6 | 0.04 % | $ 1.14 B | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | ||
|
NanoVibronix
NAOV
|
2.56 M | - | - | $ 1.08 M | ||
|
Electromed
ELMD
|
64 M | $ 24.42 | -1.13 % | $ 206 M | ||
|
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
MiMedx Group
MDXG
|
419 M | $ 4.18 | 1.33 % | $ 618 M | ||
|
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | ||
|
Cytosorbents Corporation
CTSO
|
35.6 M | $ 0.68 | -2.16 % | $ 37 M | ||
|
Aethlon Medical
AEMD
|
574 K | $ 2.29 | 5.79 % | $ 3.57 M | ||
|
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | ||
|
Sintx Technologies
SINT
|
1.02 M | $ 2.61 | 1.62 % | $ 7.24 M | ||
|
AdaptHealth Corp.
AHCO
|
3.24 B | $ 11.61 | 1.13 % | $ 1.57 B | ||
|
Myomo
MYO
|
40.9 M | $ 0.71 | 2.39 % | $ 29.7 M | ||
|
Sensus Healthcare
SRTS
|
27.5 M | $ 4.21 | 6.31 % | $ 68.7 M | ||
|
Nano-X Imaging Ltd.
NNOX
|
1.3 M | $ 2.37 | -1.29 % | $ 139 M | ||
|
Penumbra
PEN
|
1.4 B | $ 335.58 | 0.4 % | $ 13.1 B | ||
|
Invacare Corporation
IVC
|
181 M | - | - | $ 24.7 M | ||
|
EDAP TMS S.A.
EDAP
|
44.1 M | $ 3.7 | -5.33 % | $ 138 M | ||
|
Quanterix Corporation
QTRX
|
139 M | $ 4.06 | 6.15 % | $ 173 M | ||
|
OrthoPediatrics Corp.
KIDS
|
236 M | $ 16.14 | 1.45 % | $ 379 M | ||
|
Outset Medical
OM
|
119 M | $ 3.54 | 0.28 % | $ 53.8 K | ||
|
Inspire Medical Systems
INSP
|
912 M | $ 51.78 | -0.58 % | $ 1.52 B | ||
|
Pulmonx Corporation
LUNG
|
90.5 M | $ 1.33 | 1.15 % | $ 54.1 M | ||
|
Cutera
CUTR
|
49.5 M | - | -10.19 % | $ 1.99 M |